Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Product	535.84M	478.95M	405.86M	331.90M	257.66M	204.21M	163.24M	137.64M
Product Growth	107.96%	134.54%	148.63%	141.13%	104.14%	83.98%	61.69%	53.63%
Collaboration License and Other	-	29.87M	-	30.89M	24.55M	45.17M	52.97M	60.47M
Collaboration License and Other Growth	-	-33.87%	-	-48.91%	-51.75%	-31.08%	-63.17%	-57.08%

Revenue by Geography

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
United States	468.15M	421.84M	361.35M	297.33M	230.18M	181.97M	144.52M	120.45M
United States Growth	103.38%	131.82%	150.04%	146.85%	107.70%	87.16%	-	-
Rest of World	67.69M	57.11M	44.51M	34.57M	27.48M	22.24M	18.72M	17.19M
Rest of World Growth	146.30%	156.85%	137.78%	101.06%	78.51%	61.52%	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.